Serum feline pancreatic lipase immunoreactivity and trypsin-like immunoreactivity concentrations in cats with experimentally induced chronic kidney disease.
Academic Article
Overview
Research
Identity
Additional Document Info
Other
View All
Overview
abstract
BACKGROUND: Serum feline pancreatic lipase immunoreactivity (fPLI) and trypsin-like immunoreactivity (fTLI) concentrations are commonly used in cats for the evaluation of pancreatic disease. The effect of kidney disease on these tests in cats are unknown. OBJECTIVE: To investigate the effect of experimentally induced chronic kidney disease (CKD) on serum fPLI and fTLI concentrations. ANIMALS: Surplus serum samples from 20 cats with CKD experimentally induced for an unrelated project and a group of healthy control cats. METHODS: Serum fTLI and fPLI concentrations were compared between groups. RESULTS: Mean (SD) serum fTLI concentrations in 20 cats with CKD (117.863.6g/L) were significantly higher than those in healthy cats (n=32; 46.917.5g/L; P<.0001). Serum fTLI concentrations in cats with CKD were above the upper limit of the reference interval in 13 of 20 cats (65%). Serum fPLI concentrations were not significantly different between cats with induced CKD (n=18; 8.6g/L; range, 5.4-9.9g/L) and healthy cats (n=41; 7.4g/L; range, 5.0-15.2g/L; P=.12). All cats with experimentally induced CKD had serum fPLI concentrations within the reference interval. CONCLUSIONS AND CLINICAL IMPORTANCE: Decreased renal function has a clinically relevant impact on serum fTLI concentrations and potentially could interfere with a diagnosis of exocrine pancreatic insufficiency (EPI). Serum fPLI concentration was not affected by experimentally induced CKD and thus serum fPLI may be used for the diagnosis of pancreatitis in cats with kidney disease. Additional studies are needed to verify these results in cats with naturally occurring CKD.
